NET/NEC — Various Sites
Pregnancy in a patient with metastatic functioning midgut neuroendocrine tumor receiving lanreotide after peptide receptor radionuclide therapy.
Silva BT, et al
A case report from the Archives of Endocrinology and Metabolism describes a pregnant patient with metastatic neuroendocrine tumor of the ileocecal valve complicated by carcinoid syndrome who safely continued lanreotide therapy throughout pregnancy under multidisciplinary supervision, with no materna…
Source →Tumour-to-Kidney Absorbed Dose Ratios for Alpha-Emitter PRRTs Estimated with [177Lu]Lu-DOTATATE SPECT Images and Biokinetic Models: Patient Variations Impact Contribution from Redistributing Daughters.
Kvassheim M, et al
A dosimetry modelling study of 14 neuroendocrine tumour patients treated with [177Lu]Lu-DOTATATE found that alpha-emitter peptide receptor radionuclide therapies (PRRTs) using 212Pb, 225Ac, and 227Th produced large inter-patient variation in kidney absorbed dose when radioactive daughter redistribut…
Source →Notch1 supports proliferation and bioenergetic activity in a pancreatic neuroendocrine neoplasm cell line.
Forsythe SD, et al
Researchers have identified Notch1 signaling as a key driver of both cell proliferation and bioenergetic activity in a pancreatic neuroendocrine neoplasm (panNEN) cell line, suggesting it plays a functionally important role in tumor growth. The study used in vitro models to dissect how Notch1 suppor…
Source →The utility of electron microscopy in dermatopathology: cutaneous SMARCA4-deficient dedifferentiated large cell neuroendocrine carcinoma.
Jiang KJ, et al
Electron microscopy has confirmed the first two reported cases of cutaneous SMARCA4-deficient large cell neuroendocrine carcinoma (SD-LCNEC), a tumour type previously described almost exclusively as a thoracic malignancy. The two patients — a 59-year-old male with a 3 cm right flank subcutaneous nod…
Source →Network based approach identifies miR-145-3p as a central regulatory hub associated to the progression from localized to metastatic medullary thyroid carcinoma.
Citarella A, et al
A network-based study identifies miR-145-3p as the central microRNA regulatory hub driving the transition from localized (N0) to lymph-node-metastatic (N1) medullary thyroid carcinoma (MTC), exhibiting 29 altered co-expression changes and a marked loss of connectivity in metastatic tumours. Research…
Source →Integrative network toxicology and virtual knockout analysis suggest TSNA-associated molecular features in large cell neuroendocrine carcinoma.
Xiong Z, et al
A computational study linking tobacco-specific nitrosamines (TSNAs) from electronic nicotine delivery systems to large cell neuroendocrine carcinoma (LCNEC) identified EGFR, CASP3, CCND1, STAT3, and SRC as central molecular targets, with the PI3K-Akt pathway emerging as the key signaling hub connect…
Source →Surgical Management of Sporadic Pancreatic Insulinomas in a Resource-Limited Setting: A Report of Two Cases.
Seye Y, et al
Open surgical enucleation successfully resolved hypoglycemia in two patients with sporadic pancreatic insulinoma managed at a tertiary referral center in Senegal, West Africa, where advanced localization modalities including endoscopic ultrasound, somatostatin receptor scintigraphy, and selective ar…
Source →Peptide Receptor Radionucleotide Therapy for Unresectable Paediatric Head and Neck Paraganglioma in Aotearoa New Zealand.
McCall M, et al
A paediatric patient with an unresectable glomus jugulare paraganglioma treated with peptide receptor radionuclide therapy (PRRT) achieved stable disease molecularly at 12 months and radiologically at 15 months post-treatment, demonstrating a meaningful clinical benefit from this targeted approach. …
Source →Effective treatment of carcinoid syndrome with peptide receptor radionuclide therapy.
Musiałkiewicz J, et al
A study published in Endokrynologia Polska reports that peptide receptor radionuclide therapy (PRRT) constitutes an effective treatment approach for patients with carcinoid syndrome, a condition caused by hormone-secreting neuroendocrine tumors. PRRT works by delivering targeted radiation directly t…
Source →Association Between Proton Pump Inhibitor Use and Gastric Neuroendocrine Neoplasms in Autoimmune Gastritis: A Real-World Propensity Score-Matched Study From the Autoimmune gastRitis Italian netwOrk Study grOup.
Massironi S, et al
A large real-world propensity score-matched study of 153,687 patients with autoimmune gastritis (AIG) found that proton pump inhibitor (PPI) use was associated with a 49% higher risk of developing gastric neuroendocrine neoplasms (gNENs), with occurrence rates of 0.89% in PPI users versus 0.60% in n…
Source →Comparative Analysis of Characteristics and Outcomes of Patients with Early-Onset Versus Average-Onset Small Bowel Neuroendocrine Tumors.
Gao MT, et al
A large retrospective study of 3,713 patients found that early-onset small bowel neuroendocrine tumors (EO-SBNETs), affecting patients aged 30–49, are independently associated with significantly better survival compared to average-onset disease (hazard ratio 0.50, 95% CI: 0.41–0.60), with a median o…
Source →A rare case of metastatic Merkel cell carcinoma presenting without a primary cutaneous lesion: A case report.
Luo N, et al
A 44-year-old male was diagnosed with metastatic Merkel cell carcinoma (MCC) presenting with no identifiable primary skin lesion, an uncommon and diagnostically challenging phenomenon known as occult-primary MCC. The diagnosis was confirmed through comprehensive immunohistochemical profiling, includ…
Source →Primary renal neuroendocrine tumor in a 33-year-old female.
Kaur S, et al
Researchers present a rare case of a primary renal neuroendocrine tumor (NET) diagnosed in a 33-year-old female, highlighting that these tumors occur at an estimated incidence of only 0.13 per 1 million individuals due to the natural absence of neuroendocrine cells in kidney tissue. The patient unde…
Source →Anaplastic lymphoma kinase immunohistochemical positivity in high-grade pulmonary neuroendocrine carcinoma: an actionable signal or merely a shadow?
Batra U, et al
A new study of 319 high-grade pulmonary neuroendocrine carcinomas (NECs) found that ALK immunohistochemistry (IHC) positivity alone is an unreliable predictor of therapeutic benefit, with true ALK rearrangements confirmed in only 2 of 5 comprehensively profiled ALK IHC-positive cases — both detectab…
Source →Clinical Impact of Endoscopic Ultrasound-Guided Fine-Needle Biopsy in Radiologically Suspected Pancreatic Neuroendocrine Tumors.
González-Abós C, et al
A retrospective single-center study of 146 patients undergoing endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) for radiologically suspected pancreatic neuroendocrine tumors (PNETs) found that systematic biopsy led to a change in therapeutic management in 8.2% of cases (12 patients), driven…
Source →